Skip to main content
Premium Trial:

Request an Annual Quote

For Reduced Recurrences

A new study suggests treatment with the PARP inhibitor olaparib may decrease recurrences among individuals with hereditary breast cancer, the Guardian reports.

The phase 3, double-blind, randomized study, dubbed the OlympiA trial, enrolled 1,836 patients with germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants and who had already undergone surgery and chemotherapy. Half received olaparib (AstraZeneca's Lynparza) and half placebo. As the team led by Institute of Cancer Research's Andrew Tutt reports in the New England Journal of Medicine, olaparib treatment was associated with significantly longer survival free of recurrent disease. Of the women given olaparib, 85.9 percent had no recurrent disease after three years of follow up, as compared to 77.1 percent of those given placebo.

"In curative therapy trial terms, this is a really major result," Tutt tells the Guardian. It notes the results were also presented online at the American Society of Clinical Oncology meeting.

The Wall Street Journal adds that the findings "could expand the arsenal of weapons" to treat hereditary breast cancer and could "validate the pharmaceutical industry's investment" in PARP inhibitors.

It further reports that AstraZeneca plans to submit the data to regulators to seek approval for Lynparza to treat early-stage breast cancer.

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.